KT-200 / Gilead, Kymera Therap - LARVOL DELTA

KT-200 has the potential to deliver meaningful improvements in the standard of care for patients with breast cancer and other solid tumors. (GlobeNewswire) - "Gilead intends to progress the program into IND-enabling studies to support an IND filing in 2027."

IND • Breast Cancer • Solid Tumor

Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader, generating a $45 million milestone, with IND planned in 2027 (GlobeNewswire)

IND • Breast Cancer

Kymera Therapeutics…announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera, under their strategic collaboration agreement (GlobeNewswire) - "As a result, Kymera will realize a $45 million milestone payment. Gilead will progress the program into IND-enabling studies to support an IND filing in 2027....In preclinical testing, KT-200 demonstrated low-nanomolar degradation of CDK2, robust activity in CCNE1 amplified, overexpressed cell lines and in vivo tumor models, brain penetrant potential, and a favorable safety profile. Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments. To date, Kymera has realized $85 million in upfront and option exercise payments."

IND • Licensing / partnership • Preclinical • Solid Tumor